ClinicalTrials.Veeva

Menu

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Exocrine Pancreatic Dysfunction in Type 1 Diabetes

C

Ciusss de L'Est de l'Île de Montréal

Status

Completed

Conditions

Type 1 Diabetes
Exocrine Pancreatic Insufficiency

Treatments

Other: Frequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency

Study type

Observational

Funder types

Other

Identifiers

NCT05385211
1-INO-2022-1126-A-N

Details and patient eligibility

About

This study proposes to examine the contribution of CFTR variants to exocrine pancreatic insufficiency and hypoglycemic risk. Hypoglycemia is one the most frequent complications of type 1 diabetes management. Despite recent innovations, hypoglycemic risk remains high for people living with type 1 diabetes (PWT1D). Recent studies have shown that pancreatic insufficiency could affect hypoglycemic risk. Up to now, there are limited data on the association between pancreatic insufficiency and glucose control (i.e. the frequency and severity of hypoglycemic episodes as well as HbA1c levels). The main objective of this study is to determine the impact of pancreatic insufficiency on glucose control in PWT1D, and to address the role of CFTR variants as potential contributors to pancreatic insufficiency.

Full description

In this a one year cross sectional study, we plan to enroll 100 adults living with type 1 diabetes.

Patient data will then be separated into two groups based the presence or absence of exocrine pancreatic insufficiency (EPI). EPI will be defined based on the levels of pancreatic enzymes (Amylase; lipase; and trypsinogen). As the prevalence of EPI in people living with type 1 diabetes (PWT1D) is ~50%, we expect roughly the same number of individuals into both groups (with or without EPI).

Variables :

Subject data (age, gender, duration of diabetes, age at diagnostic, etc.) will be collected.

Glucose variation will be assessed with a continuous glucose monitoring system for 1 month. Briefly we will collect the number and severity of hyperglycemic events, average glucose levels, glycemic variability, etc..

From collected peripheral blood mononuclear cells (PBMCs) we will quantify CFTR function and level of expression, as well as identify CFTR variants by next generation sequencing.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Type 1 diabetes
  • Living in Montreal

Exclusion criteria

  • Pregnancy,
  • Use of corticosteroid
  • Use of medication known to have a relevant impact on glycemic control.

Trial design

100 participants in 1 patient group

People living with type 1 diabetes
Description:
Participants will be separated into two groups based on the levels of their exocrine pancreatic enzymes levels.
Treatment:
Other: Frequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency

Trial contacts and locations

1

Loading...

Central trial contact

Lise Coderre, Ph.D; Sylvie Lesage, Ph.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems